Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Ltd ( (AU:IMM) ) has issued an update.
Immutep Ltd announced a change in the director’s interest, where Mr. Pete Meyers converted 388,889 performance rights into fully paid ordinary shares. This change reflects the director’s compensation strategy, where he receives part of his fees in performance rights, aligning his interests with those of the shareholders.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company that focuses on developing immunotherapy treatments for cancer and autoimmune diseases. The company is listed on the Australian Securities Exchange under the ticker symbol IMM.
Average Trading Volume: 2,480,709
Technical Sentiment Signal: Hold
Current Market Cap: A$426.9M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.